Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21241460 | 0.86 | — | — | |
| SCHEMBL18910458 | 0.83 | GABRA1 (0.35) | CYP1A2ALDH1A1CA1CA2TSHR | |
| SCHEMBL24872828 | 0.80 | — | — | |
| SCHEMBL7937663 | 0.77 | CYP2A6 (0.35) | CYP2A6CYP1A2CD44RAF1ALDH1A1 | |
| SCHEMBL18544727 | 0.77 | TRPA1 (0.35) | CYP2A6CYP1A2CD44ALDH1A1CA1 | |
| SCHEMBL18760645 | 0.76 | ALDH1A1 (0.46) | CYP1A2ALDH1A1TSHRACHENPSR1 | |
| SCHEMBL1043318 | 0.73 | CYP2A6 (0.39) | CYP2A6CYP1A2CD44RAF1ALDH1A1 | |
| SCHEMBL1043316 | 0.73 | CYP2A6 (0.39) | CYP2A6CYP1A2CD44RAF1ALDH1A1 | |
| SCHEMBL674402 | 0.70 | CYP2A6 (0.41) | CYP2A6CYP1A2CD44RAF1ALDH1A1 | |
| SCHEMBL20117329 | 0.70 | CYP2A6 (0.41) | CYP2A6CYP1A2CD44RAF1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220216434-A1 | LIGHT-EMITTING DEVICE AND AN ELECTRONIC APPARATUS COMPRISING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-07-07 | — | — | US | disclosed |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| EP-3277684-B1 | SPECIFIC N AND P ACTIVE MATERIALS FOR ORGANIC PHOTOELECTRIC CONVERSION LAYERS IN ORGANIC PHOTODIODES | SONY CORP (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-9991452-B2 | Condensed-cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | CYP2A6 477/4885CYP1A2 38/4885CD44 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.